Drug intelligence / Profile preview

NUC-101

Development stage: Preclinical
Lead developer: Nucorion Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

NUC-101 is an investigational liver-targeted prodrug (LTP) being developed by Nucorion Pharmaceuticals for the treatment of hepatitis C virus (HCV) infection. The candidate utilizes Ligand Pharmaceuticals' proprietary LTP technology, which is designed to deliver therapeutic agents selectively to the liver by exploiting hepatic enzymes for prodrug activation. This mechanism aims to increase the concentration of the active antiviral agent within hepatocytes while reducing systemic exposure and potential side effects. Nucorion, a venture-funded biotechnology company, licensed NUC-101 as part of a broader agreement with Ligand to develop anti-cancer and anti-viral agents, with an initial focus on the China market.

Beyond the preview

Go deeper on NUC-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUC-101.

Explore the full profile